Eosinophilic esophagitis; An updated review; [Œsophagite à éosinophiles ; une revue actualisée]

Bibliographic Information
Authors: Guda M.; Almagrabi A.; Zahri M.; Alshaikh N.A.; Ghoneem E.
Journal: Nutrition Clinique et Metabolisme
Publisher: Elsevier Masson s.r.l.
Publication Date: March 2026
Volume / Issue: Volume 40 / Issue 1
Article No.: 103023
ISSN: 9850562
DOI: 10.1016/j.nupar.2025.12.002
Scopus: View on Scopus
Document Type: Article
Authors and Affiliations
Guda M., Gastroenterology Department, Theodore Bilharz Research institute, Giza, Egypt; Almagrabi A., Internal Medicine Department, Faculty of Medicine, Umm Alqura University, Makkah, Saudi Arabia, Almouwasat hospital, Dammam, Saudi Arabia; Zahri M., Mouwasat Hospital Khobar, Saudi Arabia, Tropical Medicine Department, Faculty of Medicine, Cairo University, Egypt; Alshaikh N.A., Mouwasat Hospital Khobar, Saudi Arabia; Ghoneem E., King Fahad Specialist Hospital, Dammam, Saudi Arabia, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Abstract
Chronic inflammatory esophageal illness, also known as eosinophilic esophagitis (EoE), is mostly caused by immunological responses mediated by T-helper 2 (Th2) cells. Dysphagia, chest pain, and regurgitation are some of the symptoms that can be seen in both adults and children. Specific histological criteria usually lead to a diagnosis of the condition, which is marked by eosinophilic infiltration of the esophagus. It is more common in men, and the incidence and prevalence of EoE are on the rise, especially in high-income nations. The etiology of EoE is influenced by both hereditary and environmental factors. In order to manage EoE effectively, it is necessary to deal with the inflammatory and fibrostenotic components of the condition simultaneously. Efficacious dietary elimination programs, such as the 6-food elimination diet (6FED), are currently being used as therapies, along with proton pump inhibitors (PPIs) and topical corticosteroids. Dupilumab and other monoclonal antibodies that target the interleukin-4 receptor alpha are examples of biologic therapeutics that are showing promise as treatments, especially for patients who have not responded to conventional methods. Nevertheless, studies are still being conducted to determine the medicines’ long-term safety and effectiveness in various patient populations. © 2025 Société francophone nutrition clinique et métabolisme (SFNCM).
Keywords
6-food elimination diet; Eosinophilic esophagitis; Proton pump inhibitors; T-Helper 2; corticosteroid; dupilumab; interleukin 4 receptor alpha; omeprazole; proton pump inhibitor; steroid; Article; blood flow; environmental factor; esophagus pH; food intake; highest income group; human; immune response; onset age; prevalence; six food elimination diet; Th2 cell; treatment response
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
